Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 4 recruiting now early-phase tilt small index

Solid Tumours: early-phase trial registry

4 of 10 indexed Solid Tumours trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #1,724 of 28,707 conditions by registered trial count.

10 US clinical trials · 4 currently recruiting · #1,724 of 28,707 conditions by registered trial count

Solid Tumours: 10 US clinical trials tracked, 4 recruiting.

Solid Tumours is the subject of 10 registered US clinical trials on ClinicalTrials.gov, 4 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 10 in Phase 1-2 (earlier-stage). The most active sponsor is Boehringer Ingelheim, running 3 of these trials.

Enrollment posture brief

Registry condition solid-tumours

OPEN 4 | RECR 40% | LATE 0 | EARLY 10 | RANK #1724 | SPON 3

Nearest open-share peer: Acute Myeloid Leukemia (AML) (40% recruiting · 30 trials)

Acute Leukemia of Ambiguous 80%Achondroplasia40%Solid Tumours (this)40%Accelerated Phase Chronic My20%Accidental Fall20%
Open-enrollment share among volume-matched conditions near Solid Tumours

Solid Tumours lists 4 open slots (40% of 10 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Solid Tumours on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Solid Tumours is recruiting below its size-band peers.

    4 of 10 indexed trials (40%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. One sponsor concentrates Solid Tumours research.

    Boehringer Ingelheim accounts for 3 of 10 trials (30%). 6 distinct sponsors appear on at least one study for this condition label.

  3. Most Solid Tumours trials plan to enrol fewer than 100 people.

    Median target enrolment is 69 among the 10 trials that report a genuine target (sentinel values excluded). 7 of those (70%) plan for fewer than 100 participants.

  4. Solid Tumours research is mostly interventional.

    10 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 17Phase 23

Open and recent trials

10 total, page 1 of 1

RECRUITING Phase 2 430 participants

Beamion PANTUMOR-1: A Study to Test Whether Zongertinib Helps People With Advanced Cancers With HER2 Alterations

Boehringer Ingelheim

NCT06581432

RECRUITING Phase 1 315 participants

A Phase 1/2a, First-in-human, Study of BMS-986517 in Participants With Advanced Solid Tumors

Bristol-Myers Squibb

NCT07160725

RECRUITING Phase 1 166 participants

A Phase 1, First-in-human Study of OKN4395 and Pembrolizumab in Patients With Solid Tumors

Epkin

NCT06789172

RECRUITING Phase 1 69 participants

A Study in People With Advanced Cancer (Solid Tumours) to Test Different Doses of BI 3810944 and to Find Out Whether it Helps

Boehringer Ingelheim

NCT07224425

ACTIVE NOT RECRUITING Phase 2 90 participants

A Study to Test Long-term Treatment With Brigimadlin in People With Solid Tumours Who Took Part in a Previous Study With This Medicine

Boehringer Ingelheim

NCT06619509

COMPLETED Phase 1 68 participants

Open-label Study of Topotecan and Pazopanib in Advanced Solid Tumors

GlaxoSmithKline

NCT00732420

COMPLETED Phase 2 57 participants

Pazopanib Paediatric Phase II Trial Children's Oncology Group (COG) in Solid Tumors

Novartis Pharmaceuticals

NCT01956669

COMPLETED Phase 1 54 participants

To Assess the Effects of Single Oral Dose of Selumetinib [AZD6244; ARRY-142886] [Hyd-Sulfate]), on QTc Interval in Healthy Male Volunteers

AstraZeneca

NCT02056392

COMPLETED Phase 1 39 participants

To Assess the Effect of Food on the Pharmacokinetics of Selumetinib (AZD6244; ARRY-142886) (Hyd-Sulfate) in Healthy Male Volunteers

AstraZeneca

NCT01974349

COMPLETED Phase 1 30 participants

Ispinesib In Combination With Carboplatin In Patients With Solid Tumors

GlaxoSmithKline

NCT00136578

Phase Distribution

PhaseTrial count
Phase 1 7
Phase 2 3

Top Sponsors

Named interventions

Most-linked intervention names on Solid Tumours records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

selumetinib placebo Drug
1 trials
selumetinib (oral) Drug
1 trials
SB-715992 Drug
1 trials
pazopanib Drug
1 trials
Brigimadlin Drug
1 trials
topotecan Drug
1 trials
Fed Other
1 trials
OKN4395 Drug
1 trials

US sites by state

Facility locations filed on Solid Tumours trials. A trial with sites in several states counts in each.

Texas 5 trials
California 5 trials
Tennessee 4 trials
Pennsylvania 3 trials
New York 3 trials
Florida 3 trials
Connecticut 3 trials
Washington 2 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Solid Tumours page

10 registered trials, 4 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Solid Tumours condition card totals 10 registered trials; most-linked intervention selumetinib placebo; top US site state Texas. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.